🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

164 results for “Ars” Clear

  1. sepofarsen

    ProQR Therapeutics N.V.

    Leber Congenital Amaurosis 10

    phase 3 small molecule active

    2 trials

  2. sparsentan

    Travere Therapeutics

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    3 trials

  3. sparsentan

    Travere Therapeutics

    Focal Segmental Glomerulosclerosis

    phase 3 small molecule active

    2 trials

  4. zeleciment basivarsen (DYNE-101)

    Dyne Therapeutics

    Myotonic Dystrophy Type 1 (DM1)

    phase 3 small molecule active

    1 trial

  5. A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 years of age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 other active

    1 trial

  6. A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)

    Pharm Research Associates (UK) Limited

    Congenital Hyperinsulinism (CHI)

    phase 2 other active

    1 trial

  7. A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 2 other active

    1 trial

  8. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo Ireland Designated Activity Company

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  9. ARCT-021

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab terminated

    1 trial

  10. ARCT-021 Dose 1

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab completed

    1 trial

  11. ARS-1

    Ars Pharmaceuticals Irl Limited

    Urticaria

    phase 2 small molecule completed

    1 trial

  12. ARS-1

    Ars Pharmaceuticals Irl Limited

    Asthma

    phase 2 small molecule completed

    1 trial

  13. AUTO CAR T cell therapy

    Autolus GmbH

    Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

    phase 2 mab active

    1 trial

  14. Active topical NS2 1% dermatologic cream

    Aldeyra Therapeutics

    Sjögren-Larsson Syndrome

    phase 2 small molecule completed

    1 trial

  15. Adagrasib

    Partner Therapeutics Limited

    Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2

    phase 2 small molecule active

    1 trial

  16. Arsenic Trioxide

    Teva Pharma GmbH

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  17. BCMA CART

    China SXT Pharmaceuticals

    Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

    phase 2 small molecule active

    1 trial

  18. Budenofalk 4 mg Zäpfchen, placebo to test

    Dr. Falk Pharma GmbH

    Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

    phase 2 small molecule active

    1 trial

  19. DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC

    Takeda Pharmaceuticals International AG

    Symptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years

    phase 2 small molecule active

    1 trial

  20. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Cancer Prevention Pharma (Ireland) Limited

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  21. Darinaparsin

    Alaunos Therapeutics

    HEPATOCELLULAR CARCINOMA

    phase 2 small molecule active

    1 trial

  22. Darinaparsin

    Alaunos Therapeutics

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  23. Darinaparson

    Alaunos Therapeutics

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  24. Dociparstat sodium

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources